EditForce, Inc., headquartered in Fukuoka, Japan, has created the world’s first RNA-editing technology that enables RNA-editing bases to be changed from U (uracil) to C (cytosine).  The RNA editing company also demonstrated that technology works in human cells in a joint study with Takahiro Nakamura, Faculty of Agriculture, Kyushu University.  The researchers said the study […]

Kira Pharmaceuticals says the Chinese National Medical Products Administration (NMPA) has cleared the investigational new drug (IND) application for evaluation of KP104. KP104 is a first-in-class bifunctional biologic that selectively targets the alternative and terminal complement pathways, in paroxysmal nocturnal hemoglobinuria (PNH).  This approval enables Phase 2 study of the efficacy, safety, tolerability, pharmacokinetics (PK), […]

Milestone Pharmaceuticals Inc. has announced positive topline efficacy and safety data from the phase 3 RAPID clinical trial of etripamil, the company’s investigational calcium channel blocker, in patients with paroxysmal supraventricular tachycardia (PSVT). “PSVT is an unpredictable, disruptive burden on patients, with current interventions restricted to the costly and inconvenient acute care setting,” said Bruce […]